# ROSEWOOD (NCT03332017)

> A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03332017
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: BeiGene
- Conditions: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
- Interventions: Zanubrutinib; Obinutuzumab
- Enrollment: 217
- Primary outcome: Overall Response Rate (ORR) by Independent Central Review (ICR) Assessment

## Commentary we found

- YouTube: 31
- Podcasts: 14
- X threads: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rosewood-nct03332017

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03332017", "email": "<work email>"}; the inbox owner confirms by the emailed link.